| ID | 10200 |
| Vaccine Name | Ad5-EBOV |
| Disease Name | Ebola |
| Disease Classification | Hemorrhagic |
| Virus Name | Zaire ebolavirus |
| Nucleic Acid Content | negative-sense, single-stranded RNA |
| Vaccine Type | Non-replicating viral vector |
| Vaccine Status | Phase 1 |
| Manufacturer | National Institute of Health |
| Year of Manufacturing | 2010 |
| Manufacturing Country | USA |
| Age | 18 - 50 years |
| Dosage | NA |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | Ebola virus envelope glycoprotein |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | National Institute of Allergy and Infectious Diseases |
| Other Countries | NA |
| Trade Name | NA |
| PMID | 27764560 |
| Clinical Trial ID | NCT00374309 |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ |
| Additional Links | https://www.precisionvaccinations.com/vaccines/ad5-ebov-ebola-vaccine#:~:text=CanSinBio%20Ad5%2DEBOV%20is%20an,type%2D5%20vector%20immune%20response.
|